These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 21546834)

  • 21. Predicting the magnitude of short-term CD4+ T-cell recovery in HIV-infected patients during first-line highly active antiretroviral therapy.
    Castagna A; Galli L; Torti C; D'Arminio Monforte A; Mussini C; Antinori A; Cozzi-Lepri A; Ladisa N; De Luca A; Seminari E; Gianotti N; Lazzarin A
    Antivir Ther; 2010; 15(2):165-75. PubMed ID: 20386071
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Restoration of CD4 T-cell responses to cytomegalovirus is short-lived in severely immunodeficient HIV-infected patients responding to highly active antiretroviral therapy.
    Keane NM; Price P; Lee S; Almeida CA; Stone SF; James I; French MA
    HIV Med; 2004 Nov; 5(6):407-14. PubMed ID: 15544692
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HIV-infected Rwandan women have a high frequency of long-term survival.
    Peters PJ; Karita E; Kayitenkore K; Meinzen-Derr J; Kim DJ; Tichacek A; Allen SA
    AIDS; 2007 Nov; 21 Suppl 6():S31-7. PubMed ID: 18032936
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Incidence and outcome of progressive multifocal leukoencephalopathy over 20 years of the Swiss HIV Cohort Study.
    Khanna N; Elzi L; Mueller NJ; Garzoni C; Cavassini M; Fux CA; Vernazza P; Bernasconi E; Battegay M; Hirsch HH;
    Clin Infect Dis; 2009 May; 48(10):1459-66. PubMed ID: 19348592
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Global Trends in CD4 Cell Count at the Start of Antiretroviral Therapy: Collaborative Study of Treatment Programs.
    IeDEA and COHERE Cohort Collaborations
    Clin Infect Dis; 2018 Mar; 66(6):893-903. PubMed ID: 29373672
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Second-line antiretroviral therapy in resource-limited settings: the experience of Médecins Sans Frontières.
    Pujades-Rodríguez M; O'Brien D; Humblet P; Calmy A
    AIDS; 2008 Jul; 22(11):1305-12. PubMed ID: 18580610
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Incidence and determinants of mortality and morbidity following early antiretroviral therapy initiation in HIV-infected adults in West Africa.
    Moh R; Danel C; Messou E; Ouassa T; Gabillard D; Anzian A; Abo Y; Salamon R; Bissagnene E; Seyler C; Eholié S; Anglaret X
    AIDS; 2007 Nov; 21(18):2483-91. PubMed ID: 18025885
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study Groups.
    Ledergerber B; Mocroft A; Reiss P; Furrer H; Kirk O; Bickel M; Uberti-Foppa C; Pradier C; D'Arminio Monforte A; Schneider MM; Lundgren JD;
    N Engl J Med; 2001 Jan; 344(3):168-74. PubMed ID: 11188837
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CD4+ cell-count-guided treatment interruptions in chronic HIV-infected patients with good response to highly active antiretroviral therapy.
    Boschi A; Tinelli C; Ortolani P; Moscatelli G; Morigi G; Arlotti M
    AIDS; 2004 Dec; 18(18):2381-9. PubMed ID: 15622314
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sex differences in the clinical, immunological and virological parameters of HIV-infected patients treated with HAART.
    Collazos J; Asensi V; Cartón JA
    AIDS; 2007 Apr; 21(7):835-43. PubMed ID: 17415038
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rate of CD4+ cell count increase over periods of viral load suppression: relationship with the number of previous virological failures.
    Trotta MP; Cozzi-Lepri A; Ammassari A; Vecchiet J; Cassola G; Caramello P; Vullo V; Soscia F; Chiodera A; Ladisa N; Abeli C; Cauda R; Buonuomi AR; Antinori A; d'Arminio Monforte A;
    Clin Infect Dis; 2010 Aug; 51(4):456-64. PubMed ID: 20597690
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of baseline CD4(+) T cell counts on the efficacy of nevirapine-based highly active antiretroviral therapy in Chinese HIV/AIDS patients: a prospective, multicentric study.
    Liu ZY; Guo FP; Han Y; Qiu ZF; Zuo LY; Li YL; Li TS
    Chin Med J (Engl); 2009 Oct; 122(20):2497-502. PubMed ID: 20079166
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low versus high CD4 cell count as starting point for introduction of antiretroviral treatment in resource-poor settings: a scenario-based analysis.
    Bogaards JA; Weverling GJ; Geskus RB; Miedema F; Lange JM; Bossuyt PM; Goudsmit J
    Antivir Ther; 2003 Feb; 8(1):43-50. PubMed ID: 12713063
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term follow-up of asymptomatic HIV-infected patients who discontinued antiretroviral therapy.
    Fernández Guerrero ML; Rivas P; Molina M; Garcia R; De Górgolas M
    Clin Infect Dis; 2005 Aug; 41(3):390-4. PubMed ID: 16007538
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antiretroviral therapy adherence and retention in care in middle-income and low-income countries: current status of knowledge and research priorities.
    Nachega JB; Mills EJ; Schechter M
    Curr Opin HIV AIDS; 2010 Jan; 5(1):70-7. PubMed ID: 20046150
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dysregulation of CD28 and CTLA-4 expression by CD4 T cells from previously immunodeficient HIV-infected patients with sustained virological responses to highly active antiretroviral therapy.
    Stone SF; Price P; French MA
    HIV Med; 2005 Jul; 6(4):278-83. PubMed ID: 16011533
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Incidence of HIV-related anal cancer remains increased despite long-term combined antiretroviral treatment: results from the french hospital database on HIV.
    Piketty C; Selinger-Leneman H; Bouvier AM; Belot A; Mary-Krause M; Duvivier C; Bonmarchand M; Abramowitz L; Costagliola D; Grabar S
    J Clin Oncol; 2012 Dec; 30(35):4360-6. PubMed ID: 23091098
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Choice of first-line antiretroviral therapy regimen and treatment outcomes for HIV in a middle income compared to a high income country: a cohort study.
    Dragovic G; Smith CJ; Jevtovic D; Dimitrijevic B; Kusic J; Youle M; Johnson MA
    BMC Infect Dis; 2016 Mar; 16():106. PubMed ID: 26939611
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunodeficiency at the start of combination antiretroviral therapy in low-, middle-, and high-income countries.
    ; Avila D; Althoff KN; Mugglin C; Wools-Kaloustian K; Koller M; Dabis F; Nash D; Gsponer T; Sungkanuparph S; McGowan C; May M; Cooper D; Chimbetete C; Wolff M; Collier A; McManus H; Davies MA; Costagliola D; Crabtree-Ramirez B; Chaiwarith R; Cescon A; Cornell M; Diero L; Phanuphak P; Sawadogo A; Ehmer J; Eholie SP; Li PC; Fox MP; Gandhi NR; González E; Lee CK; Hoffmann CJ; Kambugu A; Keiser O; Ditangco R; Prozesky H; Lampe F; Kumarasamy N; Kitahata M; Lugina E; Lyamuya R; Vonthanak S; Fink V; d'Arminio Monforte A; Luz PM; Chen YM; Minga A; Casabona J; Mwango A; Choi JY; Newell ML; Bukusi EA; Ngonyani K; Merati TP; Otieno J; Bosco MB; Phiri S; Ng OT; Anastos K; Rockstroh J; Santos I; Oka S; Somi G; Stephan C; Teira R; Wabwire D; Wandeler G; Boulle A; Reiss P; Wood R; Chi BH; Williams C; Sterne JA; Egger M
    J Acquir Immune Defic Syndr; 2014 Jan; 65(1):e8-16. PubMed ID: 24419071
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term evolution of CD4+ cell count in patients under combined antiretroviral therapy.
    Pantazis N; Papastamopoulos V; Paparizos V; Metallidis S; Adamis G; Antoniadou A; Psichogiou M; Chini M; Sambatakou H; Sipsas NV; Gogos C; Chrysos G; Panagopoulos P; Katsarou O; Gikas A; Touloumi G;
    AIDS; 2019 Aug; 33(10):1645-1655. PubMed ID: 31305332
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.